SEARCH:   Advanced

Blood, 15 October 2004, Vol. 104, No. 8, pp. 2467-2474. Prepublished online as a Blood First Edition Paper on May 13, 2004; DOI 10.1182/blood-2003-10-3561. This Article Full Text Full Text (PDF) All Versions of this Article: 2003-10-3561v1 104/8/2467    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Castaigne, S. Articles by Dombret, H. Search for Related Content PubMed PubMed Citation Articles by Castaigne, S. Articles by Dombret, H. Related Collections Neoplasia Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  NEOPLASIA Randomized comparison of double induction and timed-sequential induction to a "3 + 7" induction in adults with AML: long-term analysis of the Acute Leukemia French Association (ALFA) 9000 study Sylvie Castaigne, Sylvie Chevret, Eric Archimbaud, Pierre Fenaux, Dominique Bordessoule, Hervé Tilly, Thierry de Revel, Marc Simon, Brigitte Dupriez, Michel Renoux, Maud Janvier, Jean-Michel Micléa, Xavier Thomas, Christian Bastard, Claude Preudhomme, Francis Bauters, Laurent Degos, and Hervé Dombret From the Department of Onco-Hematology, Centre Hospitalier de Versailles, Le Chesnay; the Department of Biostatistics, Hôpital Saint-Louis, Paris; the Department of Hematology, Hôpital Edouard Herriot, Lyon; the Department of Hematology, Centre Hospitalier Régional Universitaire, Lille; the Department of Hematology, Centre Hospitalier Universitaire, Limoges; the Department of Hematology, Centre Henri Becquerel, Rouen; the Department of Hematology, Centre Hospitalier Inter-Armées, Clamart; the Department of Hematology, Centre Hospitalier, Lens; the Department of Hematology, Centre Hospitalier, Valenciennes; the Department of Hematology, Centre Hospitalier de la Côte Basque, Bayonne; the Department of Hematology, Centre René Huguenin, Saint Cloud; and Department of Hematology, Hôpital Saint-Louis, Paris, France. Between 1990 and 1996, we conducted a randomized trial in adults with newly diagnosed acute myeloid leukemia (AML) in order to compare relapse-free interval (RFI) after double induction (arm B), timed-sequential induction (arm C), or control "3 + 7" induction (arm A). Patients achieving complete remission (CR) after induction ± salvage received the same consolidation chemotherapy, which included a dosage stratification according to patient's age (younger or older than 50 years). This long-term analysis was performed in 592 patients (arm A/B/C, 197/198/197 patients). Overall CR rate was 76% without differences between the 3 arms, even if a salvage course was less frequently needed in arm B. Treatment-related mortality, either during the induction or the postremission phase, was not significantly higher in arms B and C than in arm A. Among the 449 CR patients, 250 relapsed (arm A/B/C, 90/87/73 patients) without significant differences in RFI in arms B and C versus arm A (P = .39 and .15, by the Gray test). However, when analyzing the 345 patients younger than 50, RFI was significantly improved in younger patients receiving timed-sequential induction (P = .038 by the Gray test), while not in those receiving double induction. Event-free survival and overall survival were similar in the 3 randomization arms. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: A. Renneville, N. Boissel, N. Gachard, D. Naguib, C. Bastard, S. de Botton, O. Nibourel, C. Pautas, O. Reman, X. Thomas, et al. The favorable impact of CEBPA mutations in patients with acute myeloid leukemia is only observed in the absence of associated cytogenetic abnormalities and FLT3 internal duplication Blood, May 21, 2009; 113(21): 5090 - 5093. [Abstract] [Full Text] [PDF] J. Braess, K. Spiekermann, P. Staib, A. Gruneisen, B. Wormann, W.-D. Ludwig, H. Serve, A. Reichle, R. Peceny, D. Oruzio, et al. Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG Blood, April 23, 2009; 113(17): 3903 - 3910. [Abstract] [Full Text] [PDF] B. D. Shah and J. E. Lancet Frontline Treatment of Acute Myeloid Leukemia: Are We Making Progress? ASCO Educational Book, January 1, 2009; 2009(1): 372 - 377. [Abstract] [Full Text] [PDF] W. P. Vaughan and J. E. Karp The Long Road to a Cure for Acute Myelocytic Leukemia: From Intensity to Specificity J. Clin. Oncol., July 20, 2008; 26(21): 3475 - 3477. [Full Text] [PDF] N. Boissel, A. Renneville, V. Biggio, N. Philippe, X. Thomas, J.-M. Cayuela, C. Terre, I. Tigaud, S. Castaigne, E. Raffoux, et al. Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype Blood, November 15, 2005; 106(10): 3618 - 3620. [Abstract] [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020